CL2014000531A1 - Composicion farmaceutica para inhalacion que comprende 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)ona; inhalador que proporciona una dosis nominal menor que 5 µg; y su uso en el tratamiento de una enfermedad pulmonar o pastologia asociada con actividad de los receptores ß2 adrenergicos. - Google Patents

Composicion farmaceutica para inhalacion que comprende 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)ona; inhalador que proporciona una dosis nominal menor que 5 µg; y su uso en el tratamiento de una enfermedad pulmonar o pastologia asociada con actividad de los receptores ß2 adrenergicos.

Info

Publication number: CL2014000531A1
Authority: CL; Chile
Prior art keywords: pastology; hydroxyquinolin; phenylethoxy; inhaler; difluoro
Prior art date: 2009-02-18

Application number

CL2014000531A

Other languages

English (en)

Inventor

Thorsten Ruf

Montejo Eric Massana

Original Assignee

Almirall Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-18

Filing date

2014-03-04

Publication date

2014-09-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40848429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000531(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-04 Application filed by Almirall Sa filed Critical Almirall Sa

2014-09-05 Publication of CL2014000531A1 publication Critical patent/CL2014000531A1/es

Links

-1 2 - {[6- (2,2-difluoro-2-phenylethoxy) hexyl] amino} -1-hydroxyethyl Chemical group 0.000 title 1
208000019693 Lung disease Diseases 0.000 title 1
102000016966 beta-2 Adrenergic Receptors Human genes 0.000 title 1
108010014499 beta-2 Adrenergic Receptors Proteins 0.000 title 1
230000000694 effects Effects 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biophysics (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL2014000531A 2009-02-18 2014-03-04 Composicion farmaceutica para inhalacion que comprende 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)ona; inhalador que proporciona una dosis nominal menor que 5 µg; y su uso en el tratamiento de una enfermedad pulmonar o pastologia asociada con actividad de los receptores ß2 adrenergicos. CL2014000531A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP09382021A EP2221297A1 (en)	2009-02-18	2009-02-18	5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases

Publications (1)

Publication Number	Publication Date
CL2014000531A1 true CL2014000531A1 (es)	2014-09-05

Family

ID=40848429

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CL2011002002A CL2011002002A1 (es)	2009-02-18	2011-08-17	Uso de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1- hidroxietil)-8-hidroxiquinolin-2-(1h)-ona, en forma de racemato, estereoisomero o mezclas de esteroisomeros o una sal o solvato del mismo para preparar un medicamento util para tratar una enfermedad pulmonar.
CL2014000531A CL2014000531A1 (es)	2009-02-18	2014-03-04	Composicion farmaceutica para inhalacion que comprende 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)ona; inhalador que proporciona una dosis nominal menor que 5 µg; y su uso en el tratamiento de una enfermedad pulmonar o pastologia asociada con actividad de los receptores ß2 adrenergicos.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CL2011002002A CL2011002002A1 (es)	2009-02-18	2011-08-17	Uso de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1- hidroxietil)-8-hidroxiquinolin-2-(1h)-ona, en forma de racemato, estereoisomero o mezclas de esteroisomeros o una sal o solvato del mismo para preparar un medicamento util para tratar una enfermedad pulmonar.

Country Status (22)

Country	Link
US (2)	US20120040941A1 (es)
EP (2)	EP2221297A1 (es)
JP (2)	JP2012518020A (es)
KR (1)	KR20110123740A (es)
CN (2)	CN103288729A (es)
AR (1)	AR075769A1 (es)
AU (1)	AU2010214855A1 (es)
BR (1)	BRPI1005932A2 (es)
CA (1)	CA2749045A1 (es)
CL (2)	CL2011002002A1 (es)
CO (1)	CO6361996A2 (es)
EA (1)	EA201101211A1 (es)
EC (1)	ECSP11011337A (es)
IL (1)	IL213980A0 (es)
MX (1)	MX2011008573A (es)
PE (1)	PE20120420A1 (es)
PH (1)	PH12014500417A1 (es)
SG (2)	SG2014009872A (es)
TW (1)	TW201031409A (es)
UY (1)	UY32435A (es)
WO (1)	WO2010094484A1 (es)
ZA (1)	ZA201104655B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2265276B1 (es)	2005-05-20	2008-02-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2302447B1 (es) *	2006-10-20	2009-06-12	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) *	2007-02-09	2009-09-11	Laboratorios Almirall S.A.	Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY32297A (es)	2008-12-22	2010-05-31	Almirall Sa	Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en)	2009-03-12	2010-09-15	Almirall, S.A.	Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2578570A1 (en)	2011-10-07	2013-04-10	Almirall, S.A.	Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en)	2012-03-20	2013-09-25	Almirall, S.A.	Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2668941A1 (en) *	2012-05-31	2013-12-04	Almirall, S.A.	Novel dosage form and formulation of abediterol

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT7920688U1 (it)	1979-02-05	1980-08-05	Chiesi Paolo	Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
DE3274065D1 (de)	1981-07-08	1986-12-11	Draco Ab	Powder inhalator
US4570630A (en)	1983-08-03	1986-02-18	Miles Laboratories, Inc.	Medicament inhalation device
FI69963C (fi)	1984-10-04	1986-09-12	Orion Yhtymae Oy	Doseringsanordning
DE3927170A1 (de)	1989-08-17	1991-02-21	Boehringer Ingelheim Kg	Inhalator
IT1237118B (it)	1989-10-27	1993-05-18	Miat Spa	Inalatore multidose per farmaci in polvere.
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
SG45171A1 (en)	1990-03-21	1998-01-16	Boehringer Ingelheim Int	Atomising devices and methods
GB9015522D0 (en)	1990-07-13	1990-08-29	Braithwaite Philip W	Inhaler
WO1992003175A1 (en)	1990-08-11	1992-03-05	Fisons Plc	Inhalation device
DE4027391A1 (de)	1990-08-30	1992-03-12	Boehringer Ingelheim Kg	Treibgasfreies inhalationsgeraet
DE69132850T2 (de)	1990-09-26	2002-05-29	Pharmachemie B.V., Haarlem	Wirbelkammer-Pulverinhalator
GB9026025D0 (en)	1990-11-29	1991-01-16	Boehringer Ingelheim Kg	Inhalation device
AU650953B2 (en)	1991-03-21	1994-07-07	Novartis Ag	Inhaler
DE4239402A1 (de)	1992-11-24	1994-05-26	Bayer Ag	Pulverinhalator
DK0674533T3 (da)	1992-12-18	1999-09-27	Schering Corp	Inhalator for medikamenter i pulverform
TR199701169T1 (xx)	1995-04-14	1998-03-21	Glaxo Wellcome Inc.	Salmeterol i�in �l��lm�� doz inhaleri.
ATE209518T1 (de)	1995-06-21	2001-12-15	Asta Medica Ag	Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator
DE19536902A1 (de)	1995-10-04	1997-04-10	Boehringer Ingelheim Int	Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE10129703A1 (de)	2001-06-22	2003-01-02	Sofotec Gmbh & Co Kg	Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10202940A1 (de)	2002-01-24	2003-07-31	Sofotec Gmbh & Co Kg	Patrone für einen Pulverinhalator
ES2195785B1 (es)	2002-05-16	2005-03-16	Almirall Prodesfarma, S.A.	Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es)	2002-12-26	2005-10-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridazin-3(2h)-ona.
ES2232306B1 (es)	2003-11-10	2006-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridazin-3(2h)-ona.
ES2251866B1 (es)	2004-06-18	2007-06-16	Laboratorios Almirall S.A.	Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es)	2004-06-21	2007-06-16	Laboratorios Almirall S.A.	Nuevos derivados de piridazin-3(2h)-ona.
ES2265276B1 (es)	2005-05-20	2008-02-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es)	2007-02-09	2009-09-11	Laboratorios Almirall S.A.	Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.

2009
- 2009-02-18 EP EP09382021A patent/EP2221297A1/en not_active Withdrawn
2010
- 2010-02-10 UY UY0001032435A patent/UY32435A/es unknown
- 2010-02-12 TW TW099104707A patent/TW201031409A/zh unknown
- 2010-02-17 AR ARP100100454A patent/AR075769A1/es unknown
- 2010-02-18 CA CA2749045A patent/CA2749045A1/en not_active Abandoned
- 2010-02-18 BR BRPI1005932A patent/BRPI1005932A2/pt not_active IP Right Cessation
- 2010-02-18 JP JP2011550475A patent/JP2012518020A/ja active Pending
- 2010-02-18 KR KR1020117018646A patent/KR20110123740A/ko not_active Ceased
- 2010-02-18 EP EP10709683A patent/EP2398772A1/en not_active Withdrawn
- 2010-02-18 WO PCT/EP2010/001027 patent/WO2010094484A1/en not_active Ceased
- 2010-02-18 CN CN2013102471118A patent/CN103288729A/zh active Pending
- 2010-02-18 SG SG2014009872A patent/SG2014009872A/en unknown
- 2010-02-18 PE PE2011001310A patent/PE20120420A1/es not_active Application Discontinuation
- 2010-02-18 CN CN2010800082336A patent/CN102317264A/zh active Pending
- 2010-02-18 AU AU2010214855A patent/AU2010214855A1/en not_active Abandoned
- 2010-02-18 US US13/202,020 patent/US20120040941A1/en not_active Abandoned
- 2010-02-18 EA EA201101211A patent/EA201101211A1/ru unknown
- 2010-02-18 SG SG2011052826A patent/SG173092A1/en unknown
- 2010-02-18 MX MX2011008573A patent/MX2011008573A/es not_active Application Discontinuation
2011
- 2011-06-23 ZA ZA2011/04655A patent/ZA201104655B/en unknown
- 2011-07-07 IL IL213980A patent/IL213980A0/en unknown
- 2011-08-12 CO CO11102789A patent/CO6361996A2/es not_active Application Discontinuation
- 2011-08-17 CL CL2011002002A patent/CL2011002002A1/es unknown
- 2011-09-16 EC EC2011011337A patent/ECSP11011337A/es unknown
2013
- 2013-10-08 US US14/048,344 patent/US20140038928A1/en not_active Abandoned
2014
- 2014-02-21 PH PH12014500417A patent/PH12014500417A1/en unknown
- 2014-03-04 CL CL2014000531A patent/CL2014000531A1/es unknown
- 2014-08-15 JP JP2014165548A patent/JP2015028029A/ja active Pending

Also Published As

Publication number	Publication date
EA201101211A1 (ru)	2012-03-30
EP2221297A1 (en)	2010-08-25
WO2010094484A1 (en)	2010-08-26
CN102317264A (zh)	2012-01-11
PE20120420A1 (es)	2012-05-09
AR075769A1 (es)	2011-04-27
JP2012518020A (ja)	2012-08-09
SG2014009872A (en)	2014-04-28
US20120040941A1 (en)	2012-02-16
ECSP11011337A (es)	2011-10-31
SG173092A1 (en)	2011-08-29
ZA201104655B (en)	2012-02-29
MX2011008573A (es)	2011-09-06
CN103288729A (zh)	2013-09-11
CA2749045A1 (en)	2010-08-26
AU2010214855A1 (en)	2011-07-21
CO6361996A2 (es)	2012-01-20
JP2015028029A (ja)	2015-02-12
UY32435A (es)	2010-05-31
BRPI1005932A2 (pt)	2017-05-02
PH12014500417A1 (en)	2015-10-19
CL2011002002A1 (es)	2011-11-11
TW201031409A (en)	2010-09-01
US20140038928A1 (en)	2014-02-06
IL213980A0 (en)	2011-08-31
KR20110123740A (ko)	2011-11-15
EP2398772A1 (en)	2011-12-28

Similar Documents

Publication	Publication Date	Title
CL2014000531A1 (es)	2014-09-05	Composicion farmaceutica para inhalacion que comprende 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)ona; inhalador que proporciona una dosis nominal menor que 5 µg; y su uso en el tratamiento de una enfermedad pulmonar o pastologia asociada con actividad de los receptores ß2 adrenergicos.
CY1122807T1 (el)	2021-05-05	Συνθεσεις, μεθοδοι και συστηματα για τη χορηγηση δυο ή περισσοτερων δραστικων παραγοντων δια της αναπνευστικης οδου
IL212568A (en)	2016-10-31	Annotated 4,1-Diazepan, Pharmaceutical Preparations Containing Them and Their Uses in the Preparation of Medicines for the Treatment of Diseases or Disorders of Mammals
IL223783B (en)	2018-06-28	Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
IL229199A (en)	2015-11-30	N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs
CL2011001544A1 (es)	2011-11-11	Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-(r)-hidroxietil}-8-hidroxiquinolin-2(1h)-ona; agonista de los receptores beta 2 adrenergico; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de asma o enfermedad pulmonar obstructiva cronica.
IL216741A (en)	2015-08-31	History of imidazolidine-2-van 1,3-imaging modalities as 17-cyp inhibitors, pharmaceutical preparations containing them, and their use in the preparation of drugs for the treatment of diseases
SV2010003581A (es)	2011-02-21	4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
IL206952A (en)	2014-09-30	History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines
IL218674A (en)	2015-11-30	Compounds that inhibit lrrk2 kinase activity, pharmacological preparations containing them, and their use in the preparation of Parkinson's disease drugs
BR112015003397A2 (pt)	2019-09-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112013032122A2 (pt)	2016-12-13	liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
ECSP14028814A (es)	2015-12-31	Nueva forma de dosificación y formulación de abediterol
WO2012156296A8 (en)	2013-02-21	Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients
IL215483A (en)	2017-07-31	6,4,2-Triple fluoro-n- [6- (1-methyl-piperidine-4-carbonyl) -pyrimidine-2-yl] -benzamide and its use in the preparation of a drug to treat or prevent migraines
BR112015028964A2 (pt)	2017-07-25	composição de suspensão, e, método para tratar uma doença ou um distúrbio pulmonar
BRPI1008727A2 (pt)	2016-03-08	derivados de azol substituídos, composição farmacêutica contendo os derivados, e método para o tratamento de doença de parkinson usando os mesmos
CL2013003497A1 (es)	2014-07-04	Producto farmacéutico de combinación en forma de polvo seco para administración por medio de un inhalador que comprende una sal de umeclidinio de un grupo definido y 100 mcg/dosis de furoato de fluticasona, sin otros activos adicionales; uso para el tratamiento de enfermedades inflamatorias o del aparato respiratorio.
ES2425315R1 (es)	2014-09-08	Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
MX2022009231A (es)	2022-09-07	Inhalador de polvo seco y metodo de uso.
IL217300A0 (en)	2012-02-29	Pyrazole derivatives' prepartion thereof, and therapeutic use thereof
AR075432A1 (es)	2011-03-30	5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona y su uso para la normalizacion de la funcion pulmonar.
CL2014003211A1 (es)	2015-06-05	Composicion farmaceutica para inhalacion que comprende aclidinio, con lactosa, que proporciona una dosis de 322 ug de base libre y aprox 140 ug de bromuro de aclidinio; un metodo para tratar una afeccion respiratoria seleccionada de asma y epoc; uso de la composicion; y un dispositivo inhalador de polvo seco calibrado que la comprende
IL219504A (en)	2016-09-29	Quinazoline Compounds, Pharmaceuticals Containing Them and Using It to Prepare Medicines to Treat Heart Failure with Congestion
EP2145889A4 (en)	2012-04-18	HETEROCYCLIC FUSED CORE DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE DERIVATIVE, AND USE OF THE COMPOSITION FOR MEDICAL PURPOSES